Advanced Cell Technology, Inc. (OTC:ACTC) is falling down again. Yesterday, the stock lost 5.56% of its price, while trading 
over 7 million shares on the market. Apparently, after a one day break, investors’ disappointment continues.
A while ago, ACT reported that it wanted to make the first human embryonic stem cell trial in Europe. However, it seem that despite their efforts to pump up the stock price with optimistic news, ACT keeps operating on the edge.
Recently, the company announced that the court “ordered” ACT was to deliver 10.7M shares of company’s stock to Cranshire Capital Master Fund, Ltd. The number of shares was considered on a conversion price of $0.0392 PS.
Threatened by a potential loss of investors’ trust, ACT finally responded to their inquiries in connection with the significant increase in trading and volatility of its common stock. However, the answers doens’t look very satisfying.
According to the company’s team, pursuant to previously disclosed judgments against the company, followed by the issuing of 70 million shares of its stock, may be impacting the trading in the company’s stock.
Obviously, issuing ACT shares might turn into a regular practice for the company, judging by its recent sales of common stock. The question is where all these sales lead to, especially when considering that the last 5K of common stock was issued to other companies.[BANNER]
Meanwhile, the financials of ACT remained disastrous. As of September 30, the company still had significant amount of cash and cash equivalents, though its liabilities were far beyond them. At the same time, the stockholders’ deficit got 50% higher and the accumulated deficit jumped over $241 million.
The management desperately continues to repay their debt financings in shares of common stock. However, ACT has no expectation of generating any meaningful revenues for a substantial period of time and it may be forced to either scale back its business efforts or curtail the business activities entirely.
